Top Markets
Coin of the day
Lepu Biopharma Co., Ltd. Lepu Biopharma Co., Ltd.

Lepu Biopharma Co., Ltd.

2157
株式のランク #9736
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise,... Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
株価
$0.53025422
最終同期: 2026-08-28
時価総額
$956.81M
変化(1日)
0.61%
変化(1年)
-52.36%
CN
取引 Lepu Biopharma Co., Ltd. (2157)

カテゴリー

Lepu Biopharma Co., Ltd.(2157)の配当利回りの履歴
Lepu Biopharma Co., Ltd.(銘柄コード: 2157)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Lepu Biopharma Co., Ltd.(2157)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)